Barclays analyst Balaji Prasad initiated coverage of Organon with an Overweight rating and $28 price target. The firm says Organon is a global play and leader in women’s specialty. The company is seeing “rapid growth” in biosimilars that can together offset the decline in its brands portfolio, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OGN:
- Organon’s JADA System reaches efficacy endpoint in published study
- Organon appoints Juan Camilo Arjona Ferreira as CMO
- 3M names Carrie Cox as Chairman of new new Health Care company
- Early notable gainers among liquid option names on August 8th
- Organon narrows FY23 revenue view to $6.25B-$6.45B, consensus $6.28B